Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid
暂无分享,去创建一个
S. Lovestone | L. Winchester | Y. Ben-Shlomo | D. Grosset | R. Wade-Martins | M. Lawton | I. Barber | B. Ryan | B. Liu | C. Bresner | M. Hu | N. Williams | Ana Belen Malpartida | Jessica Ash | Samuel G. Evetts | Alejo Holgado-Nevado | Lucinda Hopkins-Jones | Suppalak Lewis | Steve Gentlemen | S. Lewis | C. Bresner | Catherine Bresner
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] T. Friede,et al. Influence of individual, illness and environmental factors on place of death among people with neurodegenerative diseases: a retrospective, observational, comparative cohort study , 2021, BMJ supportive & palliative care.
[3] B. Mollenhauer,et al. Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders , 2021, Movement disorders : official journal of the Movement Disorder Society.
[4] W. Poewe,et al. Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population‐Based 10‐Year Study , 2021, Movement disorders : official journal of the Movement Disorder Society.
[5] K. Blennow,et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[6] K. Blennow,et al. Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics , 2021, Molecular neurodegeneration.
[7] A. Tenner,et al. The good, the bad, and the opportunities of the complement system in neurodegenerative disease , 2020, Journal of neuroinflammation.
[8] A. Singleton,et al. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression , 2020, Movement disorders : official journal of the Movement Disorder Society.
[9] K. Blennow,et al. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead , 2019, Current Opinion in Neurobiology.
[10] Y. Ben-Shlomo,et al. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort , 2019, Movement disorders : official journal of the Movement Disorder Society.
[11] J. Trojanowski,et al. Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysis , 2019, PLoS medicine.
[12] K. Blennow,et al. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay , 2019, Alzheimer's & Dementia.
[13] Paolo Eusebi,et al. CSF and blood biomarkers for Parkinson's disease , 2019, The Lancet Neurology.
[14] B. Morgan,et al. Complement in the pathogenesis of Alzheimer’s disease , 2017, Seminars in Immunopathology.
[15] Madhav Thambisetty,et al. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. , 2017, Cell systems.
[16] R. Barker,et al. Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.
[17] H. Kiyonari,et al. The Parkinson’s Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway , 2015, PLoS genetics.
[18] N. Jetté,et al. The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[19] Robert E. Burke,et al. Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.
[20] T. Montine,et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease , 2013, Annals of neurology.
[21] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[22] William T. Hu,et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease , 2011, Annals of neurology.
[23] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, PloS one.
[24] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[25] Max Kuhn,et al. Building Predictive Models in R Using the caret Package , 2008 .
[26] Cornelius J Werner,et al. Proteome analysis of human substantia nigra in Parkinson's disease , 2008, Proteome Science.
[27] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[28] Y. Ben-Shlomo,et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. , 2014, Parkinsonism & Related Disorders.
[29] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[30] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.